AstraZeneca PLC said it now expects the highly anticipated results of its phase 3 study of Imfinzi in a form of lung cancer in the second half of 2018, instead of the first half.
The U.K.-based pharmaceutical giant and its MedImmune LLC unit updated the timeline for the event-driven trial, called Mystic, and said that the change is based on current predictions.
The study is evaluating Imfinzi, also known as durvalumab, as single therapy and in combination with tremelimumab, in previously untreated patients with stage 4, first-line non-small cell lung cancer, or NSCLC.
The study is awaiting the final analysis determining overall survival and is comparing Imfinzi to platinum-based standard-of-care chemotherapy.

In July 2017, AstraZeneca said the Mystic trial failed to meet its main goal in NSCLC. Imfinzi, used in combination with tremelimumab, did not improve progression-free survival, compared to standard-of-care chemotherapy. The Mystic trial is the first phase 3 immuno-oncology combination study to have failed one of its goals.
Imfinzi is the first drug approved by the U.S. Food and Drug Administration for reducing the risk of cancer progression among stage 3 NSCLC patients whose tumors are not able to be surgically removed and whose cancer has not progressed after treatment with chemotherapy and radiation.
